These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15177782)

  • 1. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
    Coles A; Deans J; Compston A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):270-4. PubMed ID: 15177782
    [No Abstract]   [Full Text] [Related]  

  • 2. Campath-1H treatment of multiple sclerosis.
    Jones JL; Coles AJ
    Neurodegener Dis; 2008; 5(1):27-31. PubMed ID: 18075272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alemtuzumab and multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2008 Nov; 4(178):2425. PubMed ID: 19051633
    [No Abstract]   [Full Text] [Related]  

  • 5. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte depletion for leukaemia and multiple sclerosis.
    Bonn D
    Mol Med Today; 1998 Dec; 4(12):508. PubMed ID: 9866817
    [No Abstract]   [Full Text] [Related]  

  • 8. Alteration of tight junctions in intestinal transplantation induced by Campath-1H.
    Li Q; Zhang Q; Wang C; Li Y; Li Y; Li N; Li J; Wu B; Liu X
    Clin Immunol; 2009 Jul; 132(1):141-3. PubMed ID: 19369120
    [No Abstract]   [Full Text] [Related]  

  • 9. Buzz around Campath proof-of-concept trial in MS.
    Osborne R
    Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multiple sclerosis. What about treatment with monoclonal antibodies?].
    Marignier R; Confavreux C
    Rev Prat; 2010 Mar; 60(3):304-6. PubMed ID: 20402115
    [No Abstract]   [Full Text] [Related]  

  • 12. [Alemtuzumab in early multiple sclerosis].
    Killestein J; Polman CH
    Ned Tijdschr Geneeskd; 2009 Jan; 153(1-2):46. PubMed ID: 19198214
    [No Abstract]   [Full Text] [Related]  

  • 13. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
    Stilgenbauer S; Döhner H
    N Engl J Med; 2002 Aug; 347(6):452-3. PubMed ID: 12167696
    [No Abstract]   [Full Text] [Related]  

  • 15. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
    Calne R; Friend P; Moffatt S; Bradley A; Hale G; Firth J; Bradley J; Smith K; Waldmann H
    Lancet; 1998 Jun; 351(9117):1701-2. PubMed ID: 9734890
    [No Abstract]   [Full Text] [Related]  

  • 16. Remission induced by Campath-1H for thymoma-associated agranulocytosis.
    Alvares CL; Svasti-Salee D; Rowley M; Gordon-Smith EC; Marsh JC
    Ann Hematol; 2004 Jun; 83(6):398-400. PubMed ID: 14689236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

  • 18. [Multiple sclerosis: emerging treatments (1)].
    Nau JY
    Rev Med Suisse; 2010 May; 6(250):1098-9. PubMed ID: 20564872
    [No Abstract]   [Full Text] [Related]  

  • 19. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new treatment era in multiple sclerosis: clinical applications of new concepts.
    Edan G; Leray E
    J Neurol Sci; 2011 Jul; 306(1-2):170-2. PubMed ID: 20951999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.